Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 64 clinical trials
  • 0 views
  • 28 Oct, 2022
  • 13 locations
A Phase 2 Open-label Trial to Evaluate Safety, Efficacy, Tolerability, and Pharmacodynamics of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs, and a PD-1 Inhibitor in Chronic Hepatitis B Patients (OCTOPUS-1)

The purpose of this study is to evaluate efficacy of the study intervention, based on hepatitis B surface antigen (HBsAg) levels at follow-up (FU) Week 24.

  • 0 views
  • 18 Oct, 2022
  • 23 locations
HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)

A study to evaluate the antiviral effects, immunogenicity, and safety of HepTcell in treatment-naive patients with inactive Chronic Hepatitis B (CHB) and low Hepatitis B surface antigen (HBsAg

  • 5 views
  • 07 Oct, 2022
  • 21 locations
The Clinical Cure Project of Chronic Hepatitis B in China

nucleot(s)ide analogues(NAs) for some period can achieve higher hepatitis B surface antigen(HBsAg) clearance rate(which is called clinical cure or functional cure) by using pegylated interferon. Patients

interferon
hepatitis b e antigen
fibrosis
hepatitis b antigen
cirrhosis
  • 12 views
  • 14 Feb, 2022
  • 1 location
Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients

Prevention and Treatment of Chronic Hepatitis B (version 2019) of China, antiviral therapy is still recommended for some patients with inactive HBsAg carrier status who are HBV DNA positive and meet the

  • 0 views
  • 21 Apr, 2022
  • 1 location
YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)

The aim of this study is to compare the efficacy and safety of YIV-906 plus standard-of-care sorafenib versus those of sorafenib alone as a first-line systemic treatment for patients with Hepatitis B (+) associated advanced hepatocellular carcinoma. YIV-906 (PHY906, KD018) is an immune system modulator. Clinical and preclinical research suggests …

  • 3 views
  • 04 Oct, 2022
  • 20 locations
TAF to Prevent HBV Reactivation in Cancer Patients

Tenofovir alafenamide (TAF) has been approved to prevent HBV reactivation for HBsAg-positive cancer patients receiving chemotherapy. However, the real-world effectiveness and safety of TAF for

  • 0 views
  • 16 May, 2022
  • 5 locations
HBV Vaccine in Anti-core Positive Donors After LT

Anti-HBc positive liver donors frequently have occult HBV infection, and several studies in HBsAg-negative subjects have shown that there is often the detection in the liver of covalently closed

  • 0 views
  • 24 Jan, 2021
TAF (Tenofovir Alafenamide) for Preventing Progression of Liver Disease in Non-cirrhotic Chronic HBV Infection With Normal ALT and Low Viral Load.

liver fibrosis and reduction in HBsAg levels. As TAF is known to have favorable effects on the overall long-term outcome, the main clinical challenge is to identify the patients at risk of HCC and

  • 1 views
  • 12 Mar, 2022
  • 1 location
Reducing Vertical Transmission of Hepatitis B in Africa (REVERT-B)

Hepatitis B virus is an infection that can be easily transmitted from women to newborns at the time of delivery. Our objective is to identify novel options that are effective and safe in preventing perinatal transmission of hepatitis B in Africa. The REVERT-B study (Reducing Vertical Transmission of Hepatitis B …

tenofovir
lamivudine
fumarate
hepatitis
prenatal
  • 0 views
  • 04 Oct, 2022
  • 1 location